Association between hospital performance and after in-hospital cardiac arrest care

There is significant variation in survival rates after in-hospital cardiac arrest care. It is not clear whether better care is associated to better outcomes.

Hospital performance was assessed using six recommendations standardized for American hospitals participating in the program “Get with the Guidelines-Resuscitation”. 

The analysis included 149551 patients presenting in-hospital cardiac arrest in 447 centers between the years 2000 and 2012. The centers with best performance according to these guidelines also shown longer survival rates after resuscitation. Following cardiac arrest, for each 10% increase in hospital performance, chances of survival increased by 18%.  

Conclusion

Assistance quality based on the existing evidence on cardiopulmonary resuscitation varies largely throughout American hospitals and is associated to longer survival in patients presenting both shockable and non-shockable rhythms.

Monique L. Anderson
2014-11-17

Original title: Association between hospital performance and patient outcomes after in-hospital cardiac arrest care.

More articles by this author

Improved survival after out-of-hospital cardiac arrest with the use of automated external defibrillators

This study included patients presenting out of hospital cardiac arrest between 2006 and 2012 in The Netherlands to assess the impact of automated external...

Coronary flow reserve is associated to adverse events regardless angiographic severity.

This study included 329 consecutive patients derived to coronary angiography based on myocardial perfusion tests or PET scan (positron emission tomography). The extension and...

ITALIC PLUS: 6 months of double antiaggregation for no less than 24 months

Article This multicenter study included patients receiving the second generation stent XIENCE V (Abbott Vascular) randomized to 6 and 24 months of double antiaggregation therapy...

DAPT TRIAL: double antiaggregation remains controversial

Article This multicenter randomized control study with placebo was designed to determine the risks and benefits of double antiaggregation for longer than 12 months post...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...